Trial reportBritish journal of cancer2023
Chemoradiotherapy versus triplet chemotherapy as initial therapy for T4b esophageal cancer: survival results from a multicenter randomized Phase 2 trial.
Trial report in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neoadjuvant Chemoradiation Versus Chemotherapy for Esophageal Cancer: A Histology-Stratified Update Meta-Analysis of Randomized Controlled Trials.Annals of surgical oncology · 2026Pooled it
- Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.BMC medicine · 2025Trial
- Long-term nutritional outcomes after esophagectomy following induction chemotherapy versus chemoradiotherapy for T4b esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradioimmunotherapy for locally advanced esophageal squamous cell carcinoma.International journal of clinical oncology · 2026Article
- Refining the role of extended resection in multidisciplinary treatment for cT4b esophageal cancer.Journal of thoracic disease · 2026Article
- A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.ESMO gastrointestinal oncology · 2026Article
- Article
- Reassessing the role of combined organ resection in cT4b esophageal cancer: feasibility, outcomes, and future directions.Journal of thoracic disease · 2026Article
- Can combined organ resection cure T4 esophageal cancer? Insights from a multi-institutional study of incomplete resection cases.Esophagus : official journal of the Japan Esophageal Society · 2026Observational
- Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review.Annals of gastroenterological surgery · 2026Review
- The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.Frontiers in oncology · 2026Article
- Observational
- Salvage esophagectomy for unresectable locally advanced esophageal squamous cell carcinoma: Significant or not?Annals of gastroenterological surgery · 2025Review
- Conversion surgery for esophageal and esophagogastric junction cancer.International journal of clinical oncology · 2024Review
- Conversion Surgery in cT4B Esophageal Cancer: Myth or Reality?Annals of surgical oncology · 2024Article
- Causal relationship between renal function and risk of esophageal cancer: insights from Mendelian randomization.Journal of thoracic disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe report the long-term results as primary endpoint in a multicentre randomized prospective Phase 2 trial which compared chemoradiotherapy (CRT) and triplet chemotherapy (CT) as the initial therapy for conversion surgery (CS) in T4b esophageal cancer (EC).
methodsPatients with T4b EC were randomly assigned to the CRT group or CT group as initial treatment. CS was performed if resectable after initial or secondary treatment. The primary endpoint was 2-year overall survival, analysed by intention-to-treat.
resultsThe median follow-up period was 43.8 months. The 2-year survival rate was higher in the CRT group (55.1%; 95% CI: 41.1-68.3%) compared to the CT group (34.7%; 95% CI: 22.8-48.9%), although the difference was not significant (P = 0.11). Local and regional lymph node recurrence in patients undergoing R0 resection was significantly higher in the CT group compared to the CRT group (local: 30% versus 8%, respectively, P = 0.03; regional: 37% versus 8%, respectively, P = 0.002).
conclusionsUpfront CT was not superior to upfront CRT as induction therapy for T4b EC in terms of 2-year survival and was significantly inferior to upfront CRT in terms of local and regional control. REGISTRATION: The Japan Registry of Clinical Trials (s051180164).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.